liver tumor
Conditions
Interventions
Angiographic work-up will be identical to the standard procedure up to the
point of 99mTc-MAA injection. Then, 2D imaging of the controlled injection of
99mTc-MAA using IXSI is performed, followed b
Sponsors
Universitair Medisch Centrum Utrecht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Participants must have given written informed consent and comply with the requirements of the study protocol. 2. Must be aged 18 years or over. 3. Must be selected to undergo a 99mTc-MAA procedure as part of their radioembolisation treatment. 4. Sufficiently fit to undergo an additional examination time of 30-90 minutes. 5. Have a CT acquired less than 6 weeks before the pre-treatment radioembolisation procedure.
Exclusion criteria
Exclusion criteria: 1. Patients expected to require more than two injection positions for radioembolisation treatment. 2. Pregnancy or nursing. 3. Patients suffering from psychic disorders that make a comprehensive judgement impossible, such as psychosis, hallucinations and/or depression. 4. Patients who are declared incompetent. 5. Previous enrollment in the present study 6. Claustrophobia 7. The last dose of prior chemotherapy has been received less than 4 weeks prior to the planned 99mTc-MAA pretreatment procedure. 8. Radiation therapy within the last 4 weeks before the planned 99mTc-MAA pretreatment procedure 9. Major surgery within the last 4 weeks prior to the planned 99mTc-MAA pretreatment procedure 10. Any unresolved toxicity greater than Common Terminology Criteria for Adverse Events (CTCAE version 5 , see appendix 1) grade 2 from previous anti-cancer treatment 11. Body weight over 250 kg (because of maximum table load) 12. Patient length over 1.90 m (to fit IXSI geometry) 13. Patient bust line over 135 cm (to fit IXSI geometry)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety of the use of IXSI in an interventional setting. | — |
Secondary
| Measure | Time frame |
|---|---|
| Comparison of dosimetry (lung shunt fraction (LSF), tumour to non-tumour ratio (T/N ratio) and dose to liver segments) based on IXSI and conventional SPECT/CT. Visual inspection of 2D images of 99mTc-MAA administration. | — |
Countries
Netherlands
Outcome results
None listed